Presage Biosciences, a biotechnology company, has entered into a cancer research agreement with Millennium: The Takeda Oncology Company.
Under the research agreement, Millennium will gain access to Presage’s technology platform to enable non-clinical identification of effective oncology drug combinations in solid tumours.
Presage will receive upfront fees and research funding as well as development and regulatory milestones related to identification of successful drug combinations, as per the deal.
Presage Biosciences’ patented technology platform provides an unprecedented method for simultaneously analysing multiple cancer drug candidates and drug combinations within a single living tumour.
The patented Presage platform facilitates the placement of multiple ‘threads’ of candidate treatments through the skin and directly into the tumour, such controlled localisation allows for the identification of drug response directly attributable to the drug versus intrinsic cell death.
In addition, the Presage platform also has the potential for application across the drug development process, from target identification to clinical trial patient selection.
Millennium chief scientific officer Joseph Bolen said one of the company’s goals is to advance the treatment of cancer by developing therapeutic combinations.
"Presage’s technology platform allows us to obtain in-depth non-clinical in vivo data that is typically difficult to gather by conventional approaches. It is our hope that the Presage platform will help us to more rapidly and accurately prioritise our development of novel combinations," Bolen added.
Presage Biosciences president Nathan Caffo said the Presage platform provides previously inaccessible knowledge about interactions between drugs and living tumours, allowing for the selection and optimisation of promising drug combinations much earlier in the drug development process.
"We are pleased to establish this partnership with Millennium, a leader in truly innovative oncology research, to identify drug candidates for treatment of solid tumour cancers," Caffo added.